In addition to OTOF, Regeneron is committed to investigating several other targets for genetic forms of hearing loss, including GJB2. Regeneron (NASDAQ: REGN) is a leading biotechnology company ...

Shu is first expert from Asia to receive the award. According to ARO, Shu was awarded for his collaborative and continued ...

The main focus of the deal is Decibel's DB-OTO, an adeno-associated virus (AAV) gene therapy designed to correct mutations in the otoferlin or OTOF gene, which codes for a large protein expressed ...

The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...

Sensorion receives DMC recommendation to continue the Audiogene phase 1/2 trial of SENS-501: Montpellier, France Monday, February 24, 2025, 18:00 Hrs [IST] Sensorion, a pioneering ...

Audiogene is the first clinical trial in France to test a gene therapy drug, SENS-501, developed by the biotech company Sensorion, to treat children with DFNB9, a form of hereditary deafness caused by ...

Otoferlin-related hearing loss is an ultra-rare condition caused by mutations in the OTOF gene, leading to the absence of functional otoferlin protein essential for inner ear and auditory nerve ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.